https://orcid.org/0000-0002-6209-0131
References
- The ENFUMOSA cross-sectional European multicentre study of the clinical phenotypes of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470–477.
- Accordini S, Corsico AG, Braggion M, Gerbase MW, Gislason D, Gulsvik A, Heinrich J, Janson C, Jarvis D, Jõgi R, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160:93–101. doi:10.1159/000338998.
- Global Initiative for Asthma: Global strategy for asthma management and prevention, updated 2018. Available from: http://www.ginasthma.com
- Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012;6:27–40. doi:10.4137/CCRPM.S7793.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659. doi:10.1016/S0140-6736(12)60988-X.
- Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int 2014;23:282–319. doi:10.1007/s40629-014-0032-2.
- Fajt ML, Wenzel SE. Development of new therapies for severe asthma. Allergy Asthma Immunol Res 2017;9:3–14. doi:10.4168/aair.2017.9.1.3.
- Busse WW, Ring J, Huss-Marp J, Kahn JE. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010;125:803–813. doi:10.1016/j.jaci.2009.11.048.
- GlaxoSmithKline Omalizumab to mepolizumab switch study in severe eosinophilic asthma patients. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02654145. NLM Identifier: NCT02654145 [last accessed November 13, 2018].
- Dedaj R, Unsel L. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma. J Asthma 2019;56:473–474. doi:10.1080/02770903.2018.1471706.